Is Your Eyelash Serum Safe? A Physician's Guide to Reading Lash Conditioner Labels
By Susan F. Lin, M.D. | Physician · Inventor on U.S. Patent 8,206,695 (eyelash enhancement) · Contributing Author to Harry’s Cosmeticology, 9th Edition | Reviewed: June 2026
Quick Answer
An eyelash serum’s safety depends on three things you should be able to verify before applying anything near your eyes: (1) the active ingredient class is disclosed by name on the package, (2) the formulation has been independently tested for ocular safety in an IRB-protocoled study with ophthalmologist-led endpoints (visual acuity, intraocular pressure, slit-lamp findings), and (3) the manufacturer publishes clear use precautions. MD Lash Factor® offers two physician-formulated options: the original formulation uses dechloro ethylcloprostenolamide (a cosmetic-concentration prostaglandin-family compound, U.S. Patent 8,206,695) and is backed by a peer-reviewed published clinical study (Choy & Lin, Journal of Cosmetic and Laser Therapy, 2008, PMID 18569264); the new formulation is peptide-based with no prostaglandin compounds. Both have been independently evaluated through IRB-protocoled ocular safety studies and have been found safe and efficacious. The active ingredients in both formulations are fully disclosed on every package.
Why eyelash serum safety deserves a separate conversation
Eyelash serums occupy a unique position in personal care: they are applied within millimeters of the cornea, nightly for months, on a surface that drains directly into the ocular surface and tear film. The standards that apply to a face cream are simply not adequate. A lash product must be evaluated through the lens of ophthalmic safety, not just dermatologic tolerance.
The U.S. Food and Drug Administration has issued warning letters since 2011 to manufacturers of over-the-counter lash conditioners that failed to disclose active ingredients, made unsubstantiated drug-like claims, or were marketed without adequate safety documentation. The agency’s concern is not with any single ingredient family in isolation — it is with the gap between what is claimed and what is tested and disclosed.
The 4 active ingredient classes in eyelash conditioners
1. Prescription bimatoprost (Latisse and generics)
Latisse is an FDA-approved prescription drug containing bimatoprost 0.03%, a prostaglandin analog originally developed as a glaucoma medication. Requires a physician’s prescription. The labeling discloses documented potential side effects of the prostaglandin class at this therapeutic concentration: iris pigmentation change, periorbital skin darkening, periorbital fat atrophy, and conjunctival irritation. These risks are real and labeled because the compound is at a drug-level concentration.
2. Cosmetic prostaglandin-family compounds (the dominant OTC category)
The majority of over-the-counter lash conditioners — including MD Lash Factor (original formulation), Revitalash, GrandeLASH-MD, and similar products — use cosmetic-concentration prostaglandin-family compounds. These molecules are structurally related to bimatoprost but are formulated at much lower, IRB-protocoled cosmetic concentrations:
- Dechloro ethylcloprostenolamide — the patented active in original MD Lash Factor (U.S. Patent 8,206,695), developed by Dr. Susan Lin, M.D.
- Isopropyl cloprostenate — used by several legacy OTC brands
- Dechloro dihydroxy difluoro ethylcloprostenolamide — used by certain competitor formulations
Within this category, products vary enormously in how thoroughly they have been tested. Some are backed by published peer-reviewed clinical studies and ophthalmologist-led ocular safety work; others rely on marketing claims with no underlying data. This is where consumer discernment matters most.
3. Peptide-based formulations (no prostaglandin)
A newer category for consumers who prefer to avoid the prostaglandin class entirely — including those with personal or family histories of glaucoma, those concerned about pigmentation change, or those who simply want a different ingredient profile. MD Lash Factor offers a peptide-based formulation with no prostaglandin-family compounds, held to the same physician-oversight, ingredient-disclosure, and IRB-protocoled safety standards as the original.
4. Co-active conditioning ingredients
Modern eyelash conditioners include a layer of supporting actives that nourish the lash shaft and follicle. These are not the “driver” active but they meaningfully shape the appearance of lashes:
- Peptides — short amino acid chains that nourish the follicle
- Biotin (Vitamin B7) — supports keratin production in the lash shaft
- Panthenol (Pro-Vitamin B5) — humectant; improves flexibility and reduces breakage
- Thiotaine (L-ergothioneine) — a naturally derived mushroom antioxidant
- Botanical extracts — chosen for follicle-supportive properties
A well-designed conditioner pairs a clinically tested driver active with this kind of co-active layer. MD Lash Factor includes all four — biotin, panthenol, thiotaine, and a peptide complex — in both the original and the peptide-only formulations.
How to read a lash conditioner label — a physician’s checklist
| Look for (green light) | Treat with skepticism (red flag) |
|---|---|
| Full INCI ingredient list on the package | “Proprietary blend” hiding the actual driver active |
| Active ingredient class named (eg dechloro ethylcloprostenolamide; or specified peptide) | Generic “natural” or “clean” claims with no named active |
| Reference to published peer-reviewed clinical study (with PMID or DOI) | “Clinically tested” with no citable reference |
| Independent ophthalmologist-led ocular safety study (IRB, contact lens wearer enrollment) | “Ophthalmologist-tested” with no documented endpoints |
| Patent protection on the composition (signals an inventor stands behind it) | Generic formulation with no IP protection |
| Physician inventor or formulator publicly verifiable | No identifiable physician or formulator |
| Manufactured in a GMP-compliant, FDA-registered facility | Unspecified manufacturing source |
| Use precautions disclosed on the label | No precautions, no discontinue-if instructions |
| Honest 4-16 week timeline expectation | “Overnight” or “days” transformation promises (biology does not support this) |
The MD Lash Factor approach to ingredient transparency
When I formulated and patented MD Lash Factor in the 2000s, I designed the program around ingredient transparency and clinical safety evidence from the start. The peer-reviewed study my colleague and I authored in the Journal of Cosmetic and Laser Therapy (Choy & Lin, 2008; PMID 18569264) was a double-blind, randomized, placebo-controlled trial conducted under an IRB-approved protocol — the gold standard for clinical research design.
The original formulation’s active — dechloro ethylcloprostenolamide — is fully disclosed on every package and on the product page at md-factor.com. To my knowledge, the original MD Lash Factor remains the only cosmetic prostaglandin-containing eyelash conditioner backed by a published peer-reviewed clinical safety and efficacy study. Several major OTC competitors use related prostaglandin-family compounds without a comparable published evidence base.
The original published JCLT paper sits within a broader portfolio of independent clinical safety studies for the MD Lash Factor formulations, conducted by ophthalmologists under IRB-approved protocols. These include a 4-week ophthalmologist-led ocular safety study at Clinical Research Laboratories that specifically enrolled contact lens wearers and self-assessed sensitive-eye participants; independent Repeat Insult Patch Testing on 200+ subjects; the Local Lymph Node Assay (LLNA) for sensitization; the Ames mutagenicity assay; and a formal EU Safety Assessment under Regulation EC 1223/2009. Both formulations — original and peptide-based — have been evaluated through this framework and have been found safe and efficacious.
Use precautions for any lash conditioner
- Apply only to clean, dry skin along the base of the upper lash line, similar to applying liquid eyeliner. Avoid direct contact with the inside of the eye.
- Apply once nightly. More frequent application does not produce faster results and may increase irritation risk.
- Remove contact lenses before application as a precaution, even if the formula is documented contact-lens-compatible.
- Discontinue use and consult a licensed ophthalmologist if you experience eye redness, persistent irritation, changes in vision, iris pigmentation changes, eyelid skin darkening, or periorbital fat changes.
- Not intended for use during pregnancy or breastfeeding without physician guidance.
- Not intended for use if you have active eye disease (glaucoma, uveitis, recent ocular surgery) without consulting your treating physician.
- Patch test on the inner forearm for 48 hours before initial use if you have known cosmetic sensitivities.
Frequently asked questions
How can I tell if my eyelash serum is safe?
Look for: full INCI ingredient disclosure, named active ingredient class, reference to ophthalmologist-led IRB-protocoled ocular safety testing, published peer-reviewed clinical study, patent protection, clear use precautions, physician inventor publicly verifiable, GMP-compliant FDA-registered manufacturing.
What are the active ingredient classes in eyelash conditioners?
Four classes: prescription bimatoprost (drug); cosmetic prostaglandin-family compounds (eg dechloro ethylcloprostenolamide in MD Lash Factor original); peptide-based formulations (no prostaglandin); and co-active conditioning ingredients (biotin, panthenol, thiotaine, peptides, botanicals).
Is MD Lash Factor safe?
Both formulations — the original prostaglandin-family (U.S. Patent 8,206,695, JCLT 2008 published study) and the new peptide-based — have been evaluated through independent IRB-protocoled ocular safety studies including an ophthalmologist-led study that specifically enrolled contact lens wearers and sensitive-eye participants. Both have been found safe and efficacious.
Can a lash conditioner change my eye color?
Iris pigmentation change is a documented labeled side effect of prescription bimatoprost. At the lower cosmetic concentrations used in over-the-counter conditioners (including MD Lash Factor), this effect has not been observed in well-conducted clinical studies. It remains the most important reason to apply lash conditioners only as directed and to discontinue use if you notice any pigmentation change.
How long does it take to see results?
The eyelash growth cycle runs 4-11 months. Most users notice early conditioning effects within 2-3 weeks, visible length and fullness at 4-6 weeks, and maximum results at 12-16 weeks.
What should I avoid in an eyelash serum?
Undisclosed active ingredients, vague proprietary blends, no reference to ophthalmologist-led safety testing, exaggerated overnight-results claims, no patent or peer-reviewed publication, no use precautions on label, no physician inventor identifiable.
About the Author
Susan F. Lin, M.D. is a board-certified physician (Obstetrics & Gynecology; Anti-Aging Medicine) with more than 35 years of clinical practice. She is the inventor of MD Lash Factor® and holds multiple patents for eyelash-enhancement compositions, including U.S. Patent 8,206,695, Chinese Patent CN 102172344, and an international WIPO filing. Her peer-reviewed research has been published in the Journal of Cosmetic and Laser Therapy, and she is a contributing author to Harry’s Cosmeticology, 9th Edition (Part 3.3.5, Eyelashes, pp. 480-486).
Related reading
- How to Choose a Safe Lash Serum — The Clinical Evidence Framework
- Why Are My Eyelashes Falling Out? — Physician’s Guide
- Eyelash Anatomy & Growth Cycle — A Physician’s Guide
- MD Lash Factor Clinical Evidence Dossier
Featured product
- MD Lash Factor® — Physician-formulated by Dr. Susan Lin, M.D., U.S. Patent 8,206,695, peer-reviewed published clinical study (JCLT 2008, PMID 18569264). Two formulations: original (cosmetic prostaglandin-family) and new (peptide-based). Both backed by independent IRB-protocoled ocular safety studies.
Cited literature
- Choy I, Lin SF. A new eyelash care system stimulates eyelash growth: a randomized, double-blind, placebo-controlled study. J Cosmet Laser Ther. 2008;10(2):117–122. PMID: 18569264. DOI: 10.1080/14764170802054138.
Educational only; not a substitute for individualized medical advice. Information about FDA warning letters and the labeled side effects of prescription bimatoprost is drawn from publicly available regulatory and prescribing information.
